Characteristics of the Fusion Inhibitor | NIH

Updated

Jun. 03, 2021

Reviewed

Jun. 03, 2021

Appendix B: Drug Characteristics Tables

Characteristics of the Fusion Inhibitor

Appendix B, Table 7. Characteristics of the Fusion Inhibitor
Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendation	Serum Half-Life	Elimination	Adverse Events^a
Enfuvirtide (T-20) Fuzeon	Fuzeon: Injectable; supplied as lyophilized powder. Each vial contains 108 mg of T-20; reconstitute with 1.1 mL of sterile water for injection for delivery of approximately 90 mg/1 mL. Refer to prescribing information for storage instruction.	Fuzeon: T-20 90 mg/1 mL SQ twice daily	3.8 hours	Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool	Local injection site reactions (e.g., pain, erythema, induration, nodules and cysts, pruritus, ecchymosis) in almost 100% of patients Increased incidence of bacterial pneumonia HSR occurs in <1% of patients. Symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases. Re-challenge is not recommended.
^a Also see Table 20. Key: HSR = hypersensitivity reaction; SQ = subcutaneous; T-20 = enfuvirtide

Appendix B: Drug Characteristics Tables

Characteristics of the Fusion Inhibitor

Appendix B, Table 7. Characteristics of the Fusion Inhibitor
Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendation	Serum Half-Life	Elimination	Adverse Events^a
Enfuvirtide (T-20) Fuzeon	Fuzeon: Injectable; supplied as lyophilized powder. Each vial contains 108 mg of T-20; reconstitute with 1.1 mL of sterile water for injection for delivery of approximately 90 mg/1 mL. Refer to prescribing information for storage instruction.	Fuzeon: T-20 90 mg/1 mL SQ twice daily	3.8 hours	Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool	Local injection site reactions (e.g., pain, erythema, induration, nodules and cysts, pruritus, ecchymosis) in almost 100% of patients Increased incidence of bacterial pneumonia HSR occurs in <1% of patients. Symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases. Re-challenge is not recommended.
^a Also see Table 20. Key: HSR = hypersensitivity reaction; SQ = subcutaneous; T-20 = enfuvirtide

Download Guidelines

Section OnlyPDF (190.66 KB)
Full GuidelinePDF (3.89 MB)
Recommendations OnlyPDF (292.88 KB)
Tables OnlyPDF (1.68 MB)